ABEONA THERAPEUTICS INC.
Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.
Vazzano Joseph Walter (Chief Financial Officer) sold 24,880 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.17M total) on 2026-07-09.
Seshadri Vishwas (Chief Executive Officer) sold 67,971 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.47M total) on 2026-07-09.
Over the past 7 days, alphai's AI scored 1 news story mentioning ABEO (ABEONA THERAPEUTICS INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ABEO coverage spans insider activity, financial news and corporate actions.
In the last 30 days, ABEO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($10K). The most active reporter was Vazzano Joseph Walter, Chief Financial Officer, with 1 filing.
NTAP approval should improve Medicare economics for ZEVASKYN treatment centers and support broader Medicare patient access.
This is a routine insider open-market sale with no 10b5-1 plan stated, offering limited incremental signal versus broader fundamentals.
Insider selling is a near-term sentiment datapoint, but this specific Form 4 does not by itself change fundamentals or guidance.
Insider selling by a director is a modest sentiment signal, but it is not a fundamental catalyst by itself.
Routine but tradable corporate-governance update: confirms board slate and passes key equity-incentive authorization while one charter amendment fails.
alphai scores every news story that mentions ABEO with an AI model for sentiment and relevance, and aggregates insider trades from ABEONA THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.
4 min readVazzano Joseph Walter (Chief Financial Officer) sold 24,880 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.17M total) on 2026-07-09.
2 min readSeshadri Vishwas (Chief Executive Officer) sold 67,971 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.47M total) on 2026-07-09.
2 min readSilverstein Christine Berni sold 18,160 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.71 ($0.10M total) on 2026-06-15.
1 min readABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000318306 0000318306 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
3 min readABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000318306 0000318306 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
2 min readSeshadri Vishwas (Chief Executive Officer) sold 56,344 shares of ABEONA THERAPEUTICS INC. (ABEO) at an average of $5.36 ($5.30–$5.43, $0.30M total) across 2 trades over 2026-06-08 to 2026-06-09.
2 min readAbeona Therapeutics (ABEO) has granted equity awards to seven new employees to attract and retain talent, aligning with Nasdaq Listing Rule 5635(c)(4) and ensuring full vesting by the third anniversary. The clinical-stage biopharmaceutical company focuses on gene therapies for rare genetic diseases but faces significant financial challenges, as indicated by a distressed Altman Z-Score and negative operating margins. Despite a strong liquidity position, insider selling and a high beta suggest caution for investors.
3 min readThis company is making excellent progress on its treatment for a very rare and serious skin disorder.
2 min read- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay ...
3 min read
